News
-
-
PRESS RELEASE
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
FSD Pharma expands pipeline into metabolic and related disorders, focusing on weight loss and liver health solutions. Company aims to create new products to address ailments affecting millions worldwide -
-
PRESS RELEASE
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
FSD Pharma provides update on investment in Celly Nutrition Corp. for innovative beverage product aiding in alcohol metabolism and recovery. Celly Nu increases principal of term loan by $300,000 with deferred interest payment terms -
-
PRESS RELEASE
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics -
-
PRESS RELEASE
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment -
-
PRESS RELEASE
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects
-
Fresh Consulting Partners With Balanced Engineering to Propel Innovation in Autonomous Vehicles and Robotics for Nearshore OEMs and Global Suppliers
-
Ostrom Climate Announces Nature-Based Solutions Cooperation Agreement with Klima 1.5 Corp. In The Philippines
-
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
-
Kerr Introduces OptiBond Universal 360
-
NioCorp Announces Closing of Private Placement for Gross Proceeds of US$0.6 Million
-
Blue Cap AG: Annual General Meeting approves dividend of EUR 0.65 per share and appoints two new Supervisory Board members
-
EQS-Adhoc: Nakiki SE: Preliminary results for 2022 and 2023
-
Pyrum Innovations AG: Expansion of the use of Pyrum rCB in the Schwalbe tyre product range
-
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
-
Schweizer Electronic AG (SCHWEIZER) and Zollner Elektronik AG (Zollner) announce strategic partnership in the field of power embedding
-
GUILLEMOT CORPORATION: Weekly report share buyback from June 17th 2024 to June 21st 2024
-
Statement of transactions in own shares from June 17, 2024 to June 19, 2024
-
Safran: exclusive discussions to acquire Preligens
-
PR – ICADE – Alexis de Nervaux is named Head of IT and Digital Transformation and joins Icade’s Executive Committee
-
Annual Results for 2023/2024